| Literature DB >> 28819460 |
Xingshu Li1,2, Bi-Yuan Zheng1, Mei-Rong Ke1, Yongfan Zhang1, Jian-Dong Huang1, Juyoung Yoon2.
Abstract
A major challenge in photodynamic therapy (PDT) is the development of newEntities:
Keywords: activatable photosensitizer; layered double hydroxide; photodynamic therapy; phthalocyanine.; skin phototoxicity
Mesh:
Substances:
Year: 2017 PMID: 28819460 PMCID: PMC5558566 DOI: 10.7150/thno.18861
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Scheme 1Schematic illustration of the construction of LDH-ZnPcS8 nanohybrid by a co-precipiatation method: Mg, Al, and Zn in the nanohybrid were 20.87, 7.13 and 0.27 wt%, respectively. The loading percentage of ZnPcS8 in LDH-ZnPcS8 was 7.35 wt%. The probable mechanism as an aPS for PDT through the low acidity-driven release of ZnPcS8 from LDH-ZnPcS8, leading to reactivation of its photoactivities is illustrated.
Figure 1(A) SEM image and (B) TEM image of LDH-ZnPcS8.
Figure 2Photophysical and photochemical properties of LDH-ZnPcS8: (A) fluorescence spectra of ZnPcS8 and LDH-ZnPcS8 in water at 1.5 μM. (B) Photodegradation rates of DPBF (60 μM) in water (containing 0.12% DMF and 0.06% Cremophor EL) induced by ZnPcS8 and LDH-ZnPcS8 (both at 3.5 μM). A0 is the initial absorbance of the phthalocyanine probe.
Figure 3Comparison of the release profiles: (A) ZnPcS8 from LDH-ZnPcS8 and (B) S2 from LDH-S2 in PBS solutions with pH 7.4, 6.5, and 5.0 at different time intervals.
Figure 4pH-responsive fluorescence emission of LDH-ZnPcS8 at the cellular level: (A) Confocal fluorescence images of HepG2 cells after incubation with LDH-ZnPcS8 and ZnPcS8 at 0.1 μM for 30 min, followed with 25 μM nigericin solutions at pH 7.4, 6.5 and 6.0 for 20 min. Scale bars= 50 μm. (B) Comparison of the relative intracellular fluorescence intensities. Data are expressed as mean values ± standard deviation (number of cells = 50).
Figure 5Cytotoxic effects HepG2 cells: (A) LDH-ZnPcS8 and (B) ZnPcS8 in the presence and absence of light (λ > 610 nm) at a dose of 27 J•cm-2. Data are expressed as mean values ± standard deviation of three separate experiments.
Figure 6In vivo activation of LDH-ZnPcS8: (A) In vivo fluorescence imaging of mice and (B) relative fluorescence intensities after intratumoral injection with LDH-ZnPcS8 and ZnPcS8 at different time points. (C) The tumor growth curves of the four groups of mice after treatment (Drug dose: ~0.9 μmol•Kg-1. Light condition: wavelength, 685 ± 4 nm; power density, 140 mW•cm-2 ; irradiation, 30 min. Drug light interval: 5 h.). The error bar is based on standard deviation of mice per group. (D) Representative photos of mice bearing tumors after treatment. (top: saline with light. bottom: LDH-ZnPcS8 with light.) The arrows indicate tumor sites.
Figure 7Detection of potential skin phototoxicity: (A) In vivo fluorescence imaging of mice before and after intravenous injection with LDH-ZnPcS8 and ZnPcS8 at different time points. (B) Representative photos of mice after treatments with saline or LDH-ZnPcS8 with room light, sunlight, and/ or laser irradiation